Fatal anaphylactic reaction due to Basiliximab

Patricia Lovisolo Servicio de Nefrología y Trasplante Renal, Hospital Universitario Austral, Buenos Aires
Vanina Beitía Servicio de Nefrología y Trasplante Renal, Hospital Universitario Austral, Buenos Aires
Rodolfo Martin Servicio de Nefrología y Trasplante Renal, Hospital Universitario Austral, Buenos Aires
Guillermo Fragale Los autores declaran no poseer ningún interés comercial o asociativo que presente un conflicto de intereses con el trabajo presentado.

Keywords: anaphylaxis, anaphylactic reaction, basiliximab, hypersensitivity to drugs

References

Simulect (basiliximab) for Injection. Prescribing information [Internet]. Novartis Pharmaceuticals Corporation, sept. 2005. Disponible en: [citado 2015 Sept. 7].

Amlot PL, Rawlings E, Fernando ON, Griffin PJ, Heinrich G, Schreier MH, et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation. 1995;60(7):748-56.

Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl 3:S1-155.

Koch M, Becker T, Lueck R, Neipp M, Klempnauer J, Nashan B. Basiliximab induction therapy in kidney transplantation: benefits for long term allograft function after 10 years? Biologics. 2009;3:51-6.

Sheashaa HA, Bakr MA, Ismail AM, Sobh MA, Ghoneim MA. Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation: a three-year prospective randomized trial. J Nephrol. 2003;16(3):393-8.

Sheashaa HA, Bakr MA, Ismail AM, Mahmoud KM, Sobh MA, Ghoneim MA. Basiliximab induction therapy for live donor kidney transplantation: a long term follow-up of prospective randomized controlled study. Clin Exp Nephrol. 2008;12(5):376-81.

Sheashaa HA, Bakr MA, Ismail AM, Gheith OE, El-dahshan KF, Sobh MA, et al. Long-term evaluation of basiliximab induction therapy in live donor kidney transplantation: a five-year prospective randomized study. Am J Nephrol. 2005;25(3):221-5.

Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation. 1999;67(2):276-84.

Lawen JG, Davies EA, Mourad G, Oppenheimer F, Molina MG, Rostaing L, et al. Randomized doubleblind study of immunoprophylaxis with basiliximab, a

chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation. 2003 Jan 15;75(1):37-43.

Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet. 1997;350(9086):1193-8.

Ponticelli C, Yussim A, Cambi V, Legendre C, Rizzo G, Salvadori M, et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation. 2001;72(7):1261-7.

Parrott NR, Hammad AQ, Watson CJ, Lodge JP, Andrews CD. Multicenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine a monotherapy in renal transplant recipients. Transplantation. 2005;79(3):344-8.

Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ. 2003;326(7393):789.

Keown P, Balshaw R, Khorasheh S, Chong M, Marra C, Kalo Z, et al. Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation. BioDrugs. 2003;17(4):271-9.

Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation. 2004;77(2):166-76.

Massart A, Heenen S, Bejjani G, Hoang AD, Mikhalski D, Broeders E, et al. Does basiliximab induction trigger lifethreatening ARDS and shock in young patients after kidney transplantation? Clin Nephrol. 2015;83(1):61-70.

Bamgbola FO, Del Rio M, Kaskel FJ, Flynn JT. Non-cardiogenic pulmonary edema during basiliximab induction in three adolescent renal transplant patients. Pediatr Transplant. 2003;7(4):315-20.

Dolan N, Waldron M, O’Connell M, Eustace N, Carson K, Awan A. Basiliximab induced non-cardiogenic pulmonary edema in two pediatric renal transplant recipients. Pediatr Nephrol. 2009;24(11):2261-5.

Sasaki H, Chikaraishi T, Furuhata S, Tsutsumi H, Miyano S, Nakano T, et al. Anaphylactic reaction after initial exposure of Basiliximab: case reports. Transplant Proc. 2007;39(10):3457-9.

Baudouin V, Crusiaux A, Haddad E, Schandene L, Goldman M, Loirat C, et al. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation. 2003;76(3):459-63.

Published

2017-04-24

How to Cite

Lovisolo P, Beitía V, Martin R, Fragale G. Fatal anaphylactic reaction due to Basiliximab. Rev Nefrol Dial Traspl. [Internet]. 2017Apr.24 [cited 2024Nov.23];35(3):165-7. Available from: http://revistarenal.org.ar/index.php/rndt/article/view/35